GT Biopharma Inc. Common Stock
Here’s whether GT Biopharma Inc. Common Stock (GTBP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); RSI 57 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-3.02% over 10 days); weak 1-year return of -83.5%; 3-month momentum negative (-5.7%); rising volume on a downtrend (distribution, 2.06x avg). Currently 88.6% off its 52-week high. Score: -3/7.
GTBP is trading below its 200-day MA ($0.66) — a key warning sign the longer-term trend is under pressure. An RSI of 57.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -83.5% compares to +27.9% for SPY (trailed the market by 111.4%). The current 88.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.